Journal
CLINICAL INFECTIOUS DISEASES
Volume 67, Issue 9, Pages 1441-1444Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/cid/ciy340
Keywords
respiratory syncytial virus; biomarkers; mucin; vaccine
Categories
Funding
- Bill and Melinda Gates Foundation [OPP1106738]
- Bill and Melinda Gates Foundation [OPP1106738] Funding Source: Bill and Melinda Gates Foundation
Ask authors/readers for more resources
To assess MUC5AC as a biomarker for respiratory syncytial virus (RSV) disease severity, we tested nasal aspirates from RSV+ children with mild, moderate, and severe disease. Levels were significantly higher in those in the severe and moderate groups compared to mild group, indicating MUC5AC may be a useful biomarker for RSV disease severity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available